中国生物科技服务(08037.HK)淋巴瘤新药获国家药监批准临床试验
中国生物科技服务(08037.HK)公布,附属上海隆耀於1月21日,收到国家药品监督管理局批准上海隆耀名称为LY007的细胞注射液临床试验之批准通知书,注册分类为I类新药。
LY007细胞注射液是一种嵌合抗原受体T细胞(CAR-T)注射液,主要用於治疗复发难治的CD20阳性的B细胞型非霍奇金淋巴瘤,包括弥漫大B细胞淋巴瘤和转化型滤泡性淋巴瘤。
LY007细胞注射液由上海隆耀自主研发,采用了隆耀拥有自主知识产权的OX40共刺激信号设计。实验证明该设计在保障安全性的前提下,提高了产品的功效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.